1. Date of download: 9/18/2016 From: Treatment of Postmenopausal Osteoporosis with Slow-Release Sodium Fluoride: Final Report of a Randomized Controlled Trial Ann Intern Med. 1995;123(6):401-408. doi:10.7326/0003-4819-123-6-199509150-00001 Proportion of patients without new spinal fractures during 4 years of treatment in the groups receiving slow-release sodium fluoride and placebo. Figure Legend: Copyright © American College of Physicians. All rights reserved.American College of Physicians

2. Date of download: 9/18/2016 From: Treatment of Postmenopausal Osteoporosis with Slow-Release Sodium Fluoride: Final Report of a Randomized Controlled Trial Ann Intern Med. 1995;123(6):401-408. doi:10.7326/0003-4819-123-6-199509150-00001 Dependence of individual vertebral fracture rate (IVFR) on baseline L2-L4 bone density (BD) in the groups receiving slow-release sodium fluoride (SR-NaF) and placebo.Top.Bottom.All patients had radiologic evidence of osteopenia. However, six patients (three in each group) had baseline L2-L4 bone density greater than 95% that of a normal 30-year-old woman (mean). Values were probably falsely high because of severe scoliosis in three patients and compression fracture in one patient (which yielded a subnormal vertebral area) and reactive degenerative arthritis and aortic calcification, respectively, in two patients (which added extraskeletal mass). Dependence of individual vertebral fracture rate on baseline L2-L4 bone density in the group receiving sodium fluoride. Dependence of individual vertebral fracture rate on baseline L2-L4 bone density in the group receiving placebo. Figure Legend: Copyright © American College of Physicians. All rights reserved.American College of Physicians

3. Date of download: 9/18/2016 From: Treatment of Postmenopausal Osteoporosis with Slow-Release Sodium Fluoride: Final Report of a Randomized Controlled Trial Ann Intern Med. 1995;123(6):401-408. doi:10.7326/0003-4819-123-6-199509150-00001 Effect of treatment on the L2-L4 bone mineral content (BMC) and on the bone density (BD) of the femoral neck and radial shaft.PPPFor each year, the percentage change of the value from the preceding year or from baseline was calculated. Thus, a year-to-year change, rather than a cumulative change, is shown. Symbols above the bars indicate a significant change from zero, whereas symbols above the brackets show significant changes between the group receiving placebo and the group receiving slow-release sodium fluoride (SR-NaF). * < 0.05; ** < 0.01; † < 0.001. Figure Legend: Copyright © American College of Physicians. All rights reserved.American College of Physicians

4. Date of download: 9/18/2016 From: Treatment of Postmenopausal Osteoporosis with Slow-Release Sodium Fluoride: Final Report of a Randomized Controlled Trial Ann Intern Med. 1995;123(6):401-408. doi:10.7326/0003-4819-123-6-199509150-00001 Effect of treatment on the mean fasting serum fluoride level.PDashed horizontal lines indicate therapeutic window. In each study period (of 14 months), slow-release sodium fluoride (SR-NaF) or placebo was received during the first 12 months. Significant differences between the two groups at corresponding time periods are shown by †, which indicates < 0.0001. Values are presented as mean ± SE. Figure Legend: Copyright © American College of Physicians. All rights reserved.American College of Physicians